News
-
-
PRESS RELEASE
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
NanoViricides, Inc. announces the start of a Phase II Clinical Trial for NV-387 Oral Gummies as a Treatment for Ebola in DRC. NV-387 offers broad-spectrum antiviral properties against Ebola viruses -
-
-
-
-
-
-
-